PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29879072-14 2018 Since previous studies indicate a role of Th1 inflammation in TAFRO syndrome pathogenesis, tacrolimus may, therefore, be effective in treating TAFRO syndrome. Tacrolimus 91-101 negative elongation factor complex member C/D Homo sapiens 42-45 32817992-0 2020 Tacrolimus Improves the Implantation Rate in Patients with Elevated Th1/2 Helper Cell Ratio and Repeated Implantation Failure (RIF). Tacrolimus 0-10 negative elongation factor complex member C/D Homo sapiens 68-73 28689771-3 2018 Immunosuppression with tacrolimus improved pregnancy outcomes in obese and diabetic mice and repeated IF in women with elevated Th1/Th2 blood cell ratios. Tacrolimus 23-33 negative elongation factor complex member C/D Homo sapiens 128-131 28466977-4 2017 The study patients received daily dose of tacrolimus 1-3 mg based on initial Th1/Th2 cell ratio. Tacrolimus 42-52 negative elongation factor complex member C/D Homo sapiens 77-80 28466977-8 2017 CONCLUSION: We confirm our previous report that Th1/Th2 ratio can predict ART outcomes in patients with RIF and immunosuppressant treatment with tacrolimus, and peripheral blood Th1 cell levels were negatively correlated with pregnancy outcome. Tacrolimus 145-155 negative elongation factor complex member C/D Homo sapiens 48-51 23274966-8 2013 For example, tacrolimus was more potent in inhibiting CMV-specific Th1 cytokines versus Th2, whereas MPA preferentially inhibited Th2 cytokines. Tacrolimus 13-23 negative elongation factor complex member C/D Homo sapiens 67-70 29259481-8 2017 Conclusion: For recurrent miscarriage cases that show an elevated Th1/Th2 cell ratio after achieving pregnancy, immunosuppressive treatment with tacrolimus could be effective. Tacrolimus 145-155 negative elongation factor complex member C/D Homo sapiens 66-69 25394810-0 2015 Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. Tacrolimus 23-33 negative elongation factor complex member C/D Homo sapiens 138-141 25394810-1 2015 PROBLEM: We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure (RIF) patients who have elevated in T helper (Th1)/Th2 cytokine producing cell ratios. Tacrolimus 80-90 negative elongation factor complex member C/D Homo sapiens 171-174 25394810-5 2015 The daily dose of tacrolimus (1-3 mg) was determined based on the degree of the Th1/Th2 cell ratio. Tacrolimus 18-28 negative elongation factor complex member C/D Homo sapiens 80-83 25394810-10 2015 CONCLUSION: An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated Th1/Th2 ratios. Tacrolimus 49-59 negative elongation factor complex member C/D Homo sapiens 143-146 24495112-8 2014 In vitro, tacrolimus suppressed Th1 and Th2 cells but not Th17 cells. Tacrolimus 10-20 negative elongation factor complex member C/D Homo sapiens 32-35 23274966-9 2013 In a comparison of the relative potency of each drug at different dosing ranges, tacrolimus had the strongest Th1 inhibitory effect (median inhibition of interferon-gamma at 97.5%; P=0.004-0.008) followed by sirolimus (median inhibition at 82.4%). Tacrolimus 81-91 negative elongation factor complex member C/D Homo sapiens 110-113 19438859-13 2009 We propose that topical tacrolimus increases IL-10 expression in vitiligo lesions, and thereby inhibits melanocyte destruction triggered by unchecked Th1 pathways in vitiligo. Tacrolimus 24-34 negative elongation factor complex member C/D Homo sapiens 150-153 22848688-6 2012 In vitro, tacrolimus suppressed Th1 and Th2 cells in a concentration-dependent manner, but did not suppress Th17 cells even at high concentration. Tacrolimus 10-20 negative elongation factor complex member C/D Homo sapiens 32-35 21818055-5 2011 RESULTS: MPA and tacrolimus exhibited a comparable impact on T-cell response, dampening most Th1-related genes transcription and preserving regulatory T cells/Th2 molecular phenotypes. Tacrolimus 17-27 negative elongation factor complex member C/D Homo sapiens 93-96 20169301-7 2010 Long-term treatment with topical tacrolimus or a corticosteroid regimen improves atopic dermatitis and recall antigen reactivity, suggesting an improvement in the Th1/Th2-balance. Tacrolimus 33-43 negative elongation factor complex member C/D Homo sapiens 163-166 16911492-2 2006 An increased prevalence of food allergy noted specifically in children receiving tacrolimus immunosuppression supports the hypothesis that selective suppression of Th1 lymphocytes by the IL-2 inhibitor immunosuppressants CsA, and the more potent drug, tacrolimus , promotes Th2 lymphocytes and an allergic immune response. Tacrolimus 81-91 negative elongation factor complex member C/D Homo sapiens 164-167 16911492-2 2006 An increased prevalence of food allergy noted specifically in children receiving tacrolimus immunosuppression supports the hypothesis that selective suppression of Th1 lymphocytes by the IL-2 inhibitor immunosuppressants CsA, and the more potent drug, tacrolimus , promotes Th2 lymphocytes and an allergic immune response. Tacrolimus 252-262 negative elongation factor complex member C/D Homo sapiens 164-167 14966413-10 2004 CONCLUSIONS: FK506 inhibits both GvHD and GvL activity when given at clinical doses by inhibiting donor T-cell expansion, donor anti-host T-cell reactivity, and Th1 immune responses. Tacrolimus 13-18 negative elongation factor complex member C/D Homo sapiens 161-164 11407316-6 2001 In a comparative study with steroids (alclometasone dipropionate and betamethason valerate) in anti-CD3/CD2 system, tacrolimus and both steroids inhibited Th1 cytokines (IL-2, IFN-gamma), Th2 cytokines (IL-4, IL-5) and IL-3, GM-CSF (produced by both Th1 and Th2). Tacrolimus 116-126 negative elongation factor complex member C/D Homo sapiens 155-158 11407316-6 2001 In a comparative study with steroids (alclometasone dipropionate and betamethason valerate) in anti-CD3/CD2 system, tacrolimus and both steroids inhibited Th1 cytokines (IL-2, IFN-gamma), Th2 cytokines (IL-4, IL-5) and IL-3, GM-CSF (produced by both Th1 and Th2). Tacrolimus 116-126 negative elongation factor complex member C/D Homo sapiens 250-253 11053632-0 2000 Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Tacrolimus 30-40 negative elongation factor complex member C/D Homo sapiens 83-86 11053632-8 2000 Our data show that switching of immunosuppressive therapy from CsA to tacrolimus results in suppression of costimulatory ligands, adhesion molecules, Th1 responses and CD4 helper activity. Tacrolimus 70-80 negative elongation factor complex member C/D Homo sapiens 150-153